<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4135">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286493</url>
  </required_header>
  <id_info>
    <org_study_id>RC5303</org_study_id>
    <nct_id>NCT01286493</nct_id>
  </id_info>
  <brief_title>Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination</brief_title>
  <official_title>Immune Response After Booster Vaccination in HIV - Infected Patients Who Ever Received Rabies Primary Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Saovabha Memorial Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Saovabha Memorial Institute</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Booster rabies vaccination in HIV - infected patients who have ever received rabies primary
      vaccination could improve their immune response to this kind of vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have learned from the previous studies that some HIV-infected patients
      especially those with low CD4+ T-lymphocyte count had poor antibody response to rabies
      vaccination. Because of the role of the memory B cell, the investigators hypothesized that
      primary rabies immunization in HIV-infected patients could rise rapid anamnestic antibody
      response to ones after booster vaccination in case of re-exposure of rabies occur despite of
      their immunocompromised state.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rabies Neutralizing Antibody Titers</measure>
    <time_frame>Day 360</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rabies Neutralizing Antibody titers(RNab)of HIV-infected patients who receive booster rabies vaccination would be measured by Rapid Fluorescent Focus Inhibition Test(RFFIT) method at day 0, 7, 14, 28, 90,180 and 360. RNab level above 0.5 IU/ml indicate acceptable protective antibody response.
for 7 times in 1 year.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>HIV</condition>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>Rabies vaccines on day 0 and 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cell culture Rabies vaccines on day 0 and 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rabies vaccines on day 0 and 3</intervention_name>
    <description>All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,30,90,180,360</description>
    <arm_group_label>Rabies vaccines on day 0 and 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected patients 18-60 years of age

          -  Ever received primary rabies immunization

        Exclusion Criteria:

          -  currently have any active opportunistic infections

          -  have received blood or blood product within previous 3 months

          -  history of allergy to vaccine or any vaccine components

          -  currently received anti-malarial drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suda Sibunruang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Saovabha Memorial Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Saovabha Memorial Institute</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.saovabha.com</url>
    <description>http://www.saovabha.com/th/academic.asp</description>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 19, 2015</lastchanged_date>
  <firstreceived_date>January 26, 2011</firstreceived_date>
  <firstreceived_results_date>April 21, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Saovabha Memorial Institute</investigator_affiliation>
    <investigator_full_name>Suda Sibunruang</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>booster</keyword>
  <keyword>rabies</keyword>
  <keyword>immune response</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rabies Vaccines on Day 0 and 3</title>
          <description>Cell culture Rabies vaccines on day 0 and 3
rabies vaccines on day 0 and 3: All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,28,90,180,360</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Preliminary study</population>
      <group_list>
        <group group_id="B1">
          <title>Rabies Vaccines on Day 0 and 3</title>
          <description>Cell culture Rabies vaccines on day 0 and 3
rabies vaccines on day 0 and 3: All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,28,90,180,360</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="43" spread="7.8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Thailand</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>CD4+ T lymphocyte counts</title>
          <units>cell/mm^3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="489" lower_limit="94" upper_limit="1120"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rabies Neutralizing Antibody Titers</title>
        <description>Rabies Neutralizing Antibody titers(RNab)of HIV-infected patients who receive booster rabies vaccination would be measured by Rapid Fluorescent Focus Inhibition Test(RFFIT) method at day 0, 7, 14, 28, 90,180 and 360. RNab level above 0.5 IU/ml indicate acceptable protective antibody response.
for 7 times in 1 year.</description>
        <time_frame>Day 360</time_frame>
        <safety_issue>No</safety_issue>
        <population>As preliminary study, the number of participants was estimated to be above 15 - 20 cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabies Vaccines on Day 0 and 3</title>
            <description>Cell culture Rabies vaccines on day 0 and 3
rabies vaccines on day 0 and 3: All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,28,90,180,360</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Rabies Neutralizing Antibody Titers</title>
            <description>Rabies Neutralizing Antibody titers(RNab)of HIV-infected patients who receive booster rabies vaccination would be measured by Rapid Fluorescent Focus Inhibition Test(RFFIT) method at day 0, 7, 14, 28, 90,180 and 360. RNab level above 0.5 IU/ml indicate acceptable protective antibody response.
for 7 times in 1 year.</description>
            <units>IU/ml</units>
            <param>Geometric Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8.48" lower_limit="0.50" upper_limit="218.10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rabies Vaccines on Day 0 and 3</title>
          <description>Cell culture Rabies vaccines on day 0 and 3
rabies vaccines on day 0 and 3: All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,28,90,180,360</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size heterogeneous characteristics of participants Use only CD4+ T lymphocyte counts as the only immunologic surrogate marker</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr.Suda Sibunruang</name_or_title>
      <organization>Queen Saovabha Memorial Institute</organization>
      <phone>+66 2 2520161 ext 125</phone>
      <email>sudapunrin@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
